An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics

Toxicology

Volumn 216, Issue 2-3, 2005, Pages 154-167

  Vignati, Luisella ^a   Turlizzi, Elisa ^a,b   Monaci, Sonia ^a   Grossi, Pietro ^a   Kanter, Ruben De ^a   Monshouwer, Mario ^a,c  

^a Nerviano Medical Sciences Srl ^*  (Italy)

^b Siena Biotech SpA   (Italy)

^c AMGEN INC   (United States)

Author keywords

Adverse drug reactions (ADRs); CYP3A4; Cytotoxicity; In vitro screening; Metabolism mediated toxicity; Reactive metabolites

Indexed keywords

3 HYDROXYQUINIDINE; ALBENDAZOLE; AMITRIPTYLINE; CARBAMAZEPINE; COMPLEMENTARY DNA; CYTOCHROME P450 3A4; DAPSONE; DAPSONE DERIVATIVE; FLUTAMIDE; HYDROXYTAMOXIFEN; ISONIAZID; ISONICOTINIC ACID; KETOCONAZOLE; OCHRATOXIN; QUINIDINE; QUINONE DERIVATIVE; SULFOXIDE; TAMOXIFEN; TRIAZOLAM; TROGLITAZONE; XENOBIOTIC AGENT; ZIPRASIDONE;

ARTICLE; CELL ASSAY; CELL STRAIN HEPG2; CELL VIABILITY; CYTOTOXICITY; DRUG ACTIVITY; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INCUBATION TIME; LIVER CELL; METABOLITE; MICROSOME; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REDUCTION; TARGET CELL; TOXICITY TESTING;

ADENOSINE TRIPHOSPHATE; ALBENDAZOLE; AMITRIPTYLINE; ANIMALS; BUTHIONINE SULFOXIMINE; CARBAMAZEPINE; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; CHROMANS; COCULTURE TECHNIQUES; CYTOCHROME P-450 ENZYME SYSTEM; DAPSONE; ENZYME ACTIVATION; FLUTAMIDE; GLUTATHIONE; HUMANS; ISONIAZID; MICROSOMES; OCHRATOXINS; PIPERAZINES; QUINIDINE; SUBSTRATE SPECIFICITY; TAMOXIFEN; TETRAZOLIUM SALTS; THIAZOLES; THIAZOLIDINEDIONES; TOXICITY TESTS; TRIAZOLAM; XENOBIOTICS;

EID: 28244478876     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2005.08.003     Document Type: Article

References (50)

1. C. Beedham, J.J. Miceli, and R.S. Obach Ziprasidone metabolism, aldehyde oxidase, and clinical implications J. Clin. Psychopharmacol. 23 2003 229 232
2. A. Berson, C. Wolf, C. Chachaty, C. Fisch, D. Fau, D. Eugene, J. Loeper, J.C. Gauthier, P. Beaune, and D. Pompon Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450, including forms belonging to the 3A and 1A subfamilies J. Pharmacol. Exp. Ther. 265 1993 366 372
3. S. Bull, I. Langezaal, R. Clothier, and S. Coecke A Genetically engineered cell-based system for detecting metabolism-mediated toxicity Altern. Lab. Anim. 29 2001 703 716
4. M.D. Coleman Dapsone toxicity: some current perspectives Gen. Pharmacol. 26 1995 1461 1467
5. Y. Dai, and A.I. Cederbaum Cytotoxicity of acetaminophen in human cytochrome P4502E1-transfected HepG2 cells J. Pharmacol. Exp. Ther. 273 1995 1497 1505
6. S.H. Day, A. Mao, R. White, T. Schulz-Utermoehl, R. Miller, and M.G. Beconi A semi-automated method for measuring the potential for protein covalent binding in drug discovery J. Pharmacol. Toxicol. Methods 52 2005 278 285
7. D.C. Evans, A.P. Watt, D.A. Nicoll-Griffith, and T.A. Baillie Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development Chem. Res. Toxicol. 17 2004 3 16
8. S.C. Gad Active drug metabolites in drug development Curr. Opin. Pharmacol. 3 2003 98 100
9. M.J. Gomez-Lechon, M.T. Donato, J.V. Castell, and R. Jover Human hepatocytes as a tool for studying toxicity and drug metabolism Curr. Drug Metab. 4 2003 292 312
10. F.P. Guengerich Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity Chem. Res. Toxicol. 14 2001 611 650
11. J. Gut, U. Christen, N. Frey, V. Koch, and D. Stoffler Molecular mimicry in halothane hepatitis: biochemical and structural characterization of lipoylated autoantigens Toxicology 97 1995 199 224
12. A. Holownia, and J.J. Braszko Tamoxifen cytotoxicity in hepatoblastoma cells stably transfected with human CYP3A4 Biochem. Pharmacol. 67 2004 1057 1064
13. A. Jaeger, P. Sauder, J. Kopferschmitt, and F. Flesch Clinical features and management of poisoning due to antimalarial drugs Med. Toxicol. Adverse Drug Exp. 2 1987 242 273
14. N.R. Kitteringham, C. Lambert, J.L. Maggs, J. Colbert, and B.K. Park A comparative study of the formation of chemically reactive drug metabolites by human liver microsomes Br. J. Clin. Pharmacol. 26 1988 13 21
15. S.R. Knowles, J. Uetrecht, and N.H. Shear Idiosyncratic drug reactions: the reactive metabolite syndromes Lancet 356 2000 1587 1591
16. V.E. Kostrubsky, V. Ramachandran, R. Venkataramanan, K. Dorko, J.E. Esplen, S. Zhang, J.F. Sinclair, S.A. Wrighton, and S.C. Strom The use of human hepatocyte cultures to study the induction of cytochrome P-450 Drug Metab. Dispos. 27 1999 887 894
17. J. Lazarou, B.H. Pomeranz, and P.N. Corey Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies JAMA 279 1998 1200 1205
18. A.P. Li, C. Lu, J.A. Brent, C. Pham, A. Fackett, C.E. Ruegg, and P.M. Silber Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential Chem. Biol. Interact. 121 1999 17 35
19. H.L. Lin, L.A. Parsels, J. Maybaum, and P.F. Hollenberg N-Nitrosodimethylamine-mediated cytotoxicity in a cell line expressing P450 2E1: evidence for apoptotic cell death Toxicol. Appl. Pharmacol. 157 1999 117 124
20. U.A. Meyer Pharmacogenetics and adverse drug reactions Lancet 356 2000 1667 1671
21. U.A. Meyer, and J. Gut Genomics and the prediction of xenobiotic toxicity Toxicology 181-182 2002 463 466
22. X.S. Miao, and C.D. Metcalfe Determination of carbamazepine and its metabolites in aqueous samples using liquid chromatography-electrospray tandem mass spectrometry Anal. Chem. 75 2003 3731 3738
23. J.B. Mills, K.A. Rose, N. Sadagopan, J. Sahi, and S.M. de Morais Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line J. Pharmacol. Exp. Ther. 309 2004 303 309
24. T. Nakagawa, M. Sawada, F.J. Gonzalez, T. Yokoi, and T. Kamataki Stable expression of human CYP2E1 in Chinese hamster cells: high sensitivity to N,N-dimethylnitrosamine in cytotoxicity testing Mutat. Res. 360 1996 181 186
25. A.E. Nassar, and A. Lopez-Anaya Strategies for dealing with reactive intermediates in drug discovery and development Curr. Opin. Drug Discov. Dev. 7 2004 126 136
26. D.R. Nelson Cytochrome P450 and the individuality of species Arch. Biochem. Biophys. 369 1999 1 10
27. B.K. Park, N.R. Kitteringham, J.L. Maggs, M. Pirmohamed, and D.P. Williams The role of metabolic activation in drug-induced hepatotoxicity Annu. Rev. Pharmacol. Toxicol. 2004
28. B.K. Park, N.R. Kitteringham, H. Powell, and M. Pirmohamed Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity Toxicology 153 2000 39 60
29. B.K. Park, M. Pirmohamed, and N.R. Kitteringham Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective Chem. Res. Toxicol. 11 1998 969 988
30. P.A. Philip, S. Ali-Sadat, J. Doehmer, T. Kocarek, A. Akhtar, H. Lu, and K.K. Chan Use of V79 cells with stably transfected cytochrome P450 cDNAs in studying the metabolism and effects of cytotoxic drugs Cancer Chemother. Pharmacol. 43 1999 59 67
31. M. Pirmohamed, N.R. Kitteringham, A.M. Breckenridge, and B.K. Park The effect of enzyme induction on the cytochrome P450-mediated bioactivation of carbamazepine by mouse liver microsomes Biochem. Pharmacol. 44 1992 2307 2314
32. H.C. Rawden, G.O. Kokwaro, S.A. Ward, and G. Edwards Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes Br. J. Clin. Pharmacol. 49 2000 313 322
33. S. Rendic, and F.J. Di Carlo Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors Drug Metab. Rev. 29 1997 413 580
34. R.J. Riley, J.L. Maggs, C. Lambert, N.R. Kitteringham, and B.K. Park An in vitro study of the microsomal metabolism and cellular toxicity of phenytoin, sorbinil and mianserin Br. J. Clin. Pharmacol. 26 1988 577 588
35. R.J. Riley, P. Roberts, M.D. Coleman, N.R. Kitteringham, and B.K. Park Bioactivation of dapsone to a cytotoxic metabolite: in vitro use of a novel two compartment system which contains human tissues Br. J. Clin. Pharmacol. 30 1990 417 426
36. C. Rodriguez-Antona, M.T. Donato, A. Boobis, R.J. Edwards, P.S. Watts, J.V. Castell, and M.J. Gomez-Lechon Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells Xenobiotica 32 2002 505 520
37. D. Roymans, P. Annaert, J. Van Houdt, A. Weygers, J. Noukens, C. Sensenhauser, J. Silva, C. Van Looveren, J. Hendrickx, G. Mannens, and W. Meuldermans Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes Drug Metab. Dispos. 33 2005 1004 1016
38. A. Schneider, W.A. Schmalix, V. Siruguri, E.M. de Groene, G.J. Horbach, B. Kleingeist, D. Lang, R. Bocker, C. Belloc, P. Beaune, H. Greim, and J. Doehmer Stable expression of human cytochrome P450 3A4 in conjunction with human NADPH-cytochrome P450 oxidoreductase in V79 Chinese hamster cells Arch. Biochem. Biophys. 332 1996 295 304
39. A.Y. Simarro Doorten, S. Bull, M.A. van der Doelen, and J. Fink-Gremmels Metabolism-mediated cytotoxicity of ochratoxin A Toxicol. In Vitro 18 2004 271 277
40. J.P. Uetrecht New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system Chem. Res. Toxicol. 12 1999 387 395
41. C.R. Valentine, J.L. Valentine, J. Seng, J. Leakey, and D. Casciano The use of transgenic cell lines for evaluating toxic metabolites of carbamazepine Cell Biol. Toxicol. 12 1996 155 165
42. R. Venkataramanan, V. Ramachandran, B.J. Komoroski, S. Zhang, P.L. Schiff, and S.C. Strom Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures Drug Metab. Dispos. 28 2000 1270 1273
43. A. Walubo, P. Smith, and P.I. Folb The role of oxygen free radicals in isoniazid-induced hepatotoxicity Methods Find. Exp. Clin. Pharmacol. 20 1998 649 655
44. Y.H. Wen, J. Sahi, E. Urda, S. Kulkarni, K. Rose, X. Zheng, J.F. Sinclair, H. Cai, S.C. Strom, and V.E. Kostrubsky Effects of bergamottin on human and monkey drug-metabolizing enzymes in primary cultured hepatocytes Drug Metab. Dispos. 30 2002 977 984
45. G.H. Wolfgang, and D.E. Johnson Web resources for drug toxicity Toxicology 173 2002 67 74
46. D. Wu, and A.I. Cederbaum Ethanol cytotoxicity to a transfected HepG2 cell line expressing human cytochrome P4502E1 J. Biol. Chem. 271 1996 23914 23919
47. Y. Yamamoto, H. Yamazaki, T. Ikeda, T. Watanabe, H. Iwabuchi, M. Nakajima, and T. Yokoi Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells Drug Metab. Dispos. 30 2002 155 160
48. S. Yoshitomi, K. Ikemoto, J. Takahashi, H. Miki, M. Namba, and S. Asahi Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology Toxicol. In Vitro 15 2001 245 256
49. K. Zhang, M. Chew, E.B. Yang, K.P. Wong, and P. Mack Modulation of cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms Mol. Pharmacol. 59 2001 837 843
50. S. Zhou, E. Chan, W. Duan, M. Huang, and Y.Z. Chen Drug bioactivation, covalent binding to target proteins and toxicity relevance Drug Metab. Rev. 37 2005 41 213